No association between whole-body UVA1 phototherapy and skin cancers in humans: a cancer registry linkage study.

Ultraviolet A1 (UVA1) phototherapy was first developed in the 1980s.(1) Its use started in the UK in Dundee in 1996.(2) It is not available in most centres despite being useful for some of the sclerosing/fibrosing conditions and granulomatous conditions. Where available, for some individuals, it can be very helpful for other indications such as atopic eczema.(3) A concern is that sufficient exposures might increase the risk of skin cancer.(4) Itt has been shown to produce cyclobutane-pyrimidine dimers in humans,(5) and so has the potential to be carcinogenic.